Antengene Biologics Limited

Open enrollment with an early-phase pipeline tilt

According to ClinicalTrials.gov-derived indexes, Antengene Biologics Limited sits in the upper half of US sponsors by registered trial count (#4,885 of 15,742 sponsors by registered trial count).

2 total trials 1 currently recruiting early-phase tilt upper half by trial count

Antengene Biologics Limited: 2 sponsored US clinical trials, 1 recruiting.

Antengene Biologics Limited sponsors 2 registered US clinical trials on ClinicalTrials.gov, 1 of them currently recruiting. 0 of these trials are in Phase 3-4 (later-stage) and 2 in Phase 1-2 (earlier-stage). The most-studied condition in this pipeline is B-cell Non-Hodgkin Lymphomas, with 1 trials.

Mid-pack sponsor footprint

Antengene Biologics Limited is in the upper half of sponsors by trial count (#4,885 of 15,742 sponsors by registered trial count). Use the pipeline list and therapeutic areas to see what drives that mid-pack volume.

What is open in the Antengene Biologics Limited pipeline

1 recruiting of 2 indexed (50% open).

Phase mix: 0 late (III/IV) vs 2 early (I/II) (early-phase heavy).

Top condition: B-cell Non-Hodgkin Lymphomas (1 trial), 1 other listed.

How open-pipeline share is computed

Recruiting share is recruiting_count divided by trial_count for this sponsor in the public registry export. Status can change between pulls; treat the figure as a research-attention snapshot, not product availability.

Antengene Biologics Limited: open-pipeline peers nationwide

Peers matched on 2 registered trials and 50% open enrollment, not the therapeutic-area sidebar.

Antengene Biologics Limited sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 1.522.533.544.5 0%20%40%60% Total trials Recruiting share Antengene Biologics Limited1200 Pharma1ST Biotherapeutics3 Waves Wellness3EO Health3ive Labs60 Degrees Pharmaceuticals7 Hills PharmaAbcentra
Antengene Biologics Limited sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Antengene Biologics Limited sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 2 trials (± recruiting share)

Sponsors near 50% open enrollment (± trial volume)

What to do with this Antengene Biologics Limited page

2 registered trials is a research-attention snapshot, not an endorsement of Antengene Biologics Limited or any single study.

  • 1 of Antengene Biologics Limited's trials are currently recruiting, check each one's own eligibility criteria before contacting a site. Browse recruiting trials
  • B-cell Non-Hodgkin Lymphomas is the condition Antengene Biologics Limited studies most, compare against other sponsors active in the same condition before evaluating a specific study. See B-cell Non-Hodgkin Lymphomas trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Antengene Biologics Limited pipeline card: 2 registered trials from official public datasets.Report a data error.